Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CureVac NV
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives
Public Company Edition: Aileron, Talaris and Frequency said they will reduce expenses and seek options for maximizing shareholder returns under tough stock market conditions. However, CureVac and Supernus are among firms recently able to access new cash – $250m and $150m, respectively.
CureVac Converts To Modified mRNA And Stock Soars
CureVac, formerly a cheerleader of the unmodified mRNA approach, is embracing the modified version for its vaccine portfolio, a move that has gone down well with the investment community.
RNA Medicines: Advancements Leading To Investments
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Technologies
- Other Names / Subsidiaries
- CureVac GmbH
- CureVac BV
- Frame Therapeutics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.